Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations

Acta Psychiatrica Scandinavica

Volumn 106, Issue 5, 2002, Pages 323-330

  Freudenreich, O ^a,b   Goff, D C ^b  

^a Freedom Trail Clinic   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antipsychotic agents; Drug therapy combination; Schizophrenia; Treatment outcome

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; ZIPRASIDONE;

AKATHISIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPULSION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG POTENTIATION; ECONOMIC ASPECT; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERSALIVATION; MONOTHERAPY; ORTHOSTATIC HYPOTENSION; PRIAPISM; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; CLOZAPINE; DELIRIUM; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; RISK; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SIALORRHEA; TREATMENT OUTCOME;

EID: 0036838758     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0447.2002.01331.x     Document Type: Review

References (51)

1. Wang PS, West JC, Tanielian T, Pincus HA. Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull 2000;26:451-457.
2. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry 1999;60(Suppl. 10):20-30.
3. Peacock L, Gerlach J. Clozapine treatment in Denmark. Concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J Clin Psychiatry 1994;55:44-49.
4. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 1995;13:177-213.
5. Stahl SM. Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret? [Brainstorms]. J Clin Psychiatry 1999;60:425-426.
6. Chong SA, Remington G. Clozapine augmentation. Safety and efficacy. Schizophr Bull 2000;26:421-440.
7. Shiloh R, Zemishlany Z, Aizenberg D et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997;171:569-573.
8. Potter WZ, Ko GN, Zhang LD, Yan W. Clozapine in China. A review and preview of US/PRC collaboration. Psychopharmacology 1989;99:S87-S97.
9. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996;57:395-397.
10. Degroot IW, Heck AH, Van Harten PN. Addition of risperidone to clozapine therapy in chronically psychotic inpatients (letter). J Clin Psychiatry 2001;62:129-130.
11. Taylor CG, Flynn SW, Altman S, Ehmann T, MacEwan GW, Honer WG. An open trial of risperidone augmentation of partial response to clozapine. Schizophr Res 2001;48:155-158.
12. Morera AL, Barreiro P, Cano-Munoz JL. Risperidone and clozapine combination for the treatment of refractory schizophrenia. Acta Psychiatr Scand 1999;99:305-307.
13. Raskin S, Katz G, Zislin Z, Knobler HY, Durst R. Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation. Acta Psychiatr Scand 2000;101:334-336.
14. Friedman J, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol Psychiatry 1997;42:522-523.
15. Takhar J. Pimozide augmentation in a patient with drug-resistant psychosis previously treated with olanzapine (letter). J Psychiatry Neurosci 1999;24:248-249.
16. Mowerman S, Siris SG. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. Ann Clin Psychiatry 1996;8:193-197.
17. Raskin S, Durst R, Katz G, Zislin J. Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia. J Clin Psychopharmacol 2000;20:500-503.
18. Lerner V, Chudakova B, Kravets S, Pplyakova I. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report. Clin Neuropharmacol 2000;23:284-286.
19. Naber D, Holzbach R, Perro C, Hippius H. Clinical management of clozapine patients in relation to efficacy and side effects. Br J Psychiatry 1992;160(Suppl. 17):54-59.
20. Henderson DC, Goff DC, Connolly CE, Borba CP, Hayden D. Risperidone added to clozapine. Impact on serum prolactin levels. J Clin Psychiatry 2001;62:605-608.
21. Chong SA, Tan CH, Lee HS. Atrial ectopics with clozapine-risperidone combination (letter). J Clin Psychopharmacol 1997;17:130-131.
22. Cyhong SA, Tan CH, Lee HS. Hoarding and clozapine-risperidone combination (letter). Can J Psychiatry 1996;41: 315-316.
23. Godleski LS, Sernyak MJ. Agranuloytosis after addition of risperidone to clozapine treatment (letter). Am J Psychiatry 1996;153:735-736.
24. Gomberg RF. Interaction between olanzapine and haloperidol (letter). J Clin Psychopharmacol 1999;19:272-273.
25. Seger A, Lamberti JS. Priapism associated with polypharmacy (letter). J Clin Psychiatry 2001:62:128.
26. Koreen AR, Lieberman JA, Kronig M. Cooper TB. Cross-tapering clozapine and risperidone (letter). Am J Psychiatry 1995:152:1690.
27. Tyson SC, Devane CL, Risch CC. Pharmacokinetic interaction between risperidone and clozapine (letter). Am J Psychiatry 1995;152:1401-1402.
28. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998;173:325-329.
29. Nordstrom AL, Farde L, Wiesel FA et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-235.
30. Kapur S, Zipursky RB, Remington G. Clinical and theoetical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-293.
31. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 2000;25:161-166.
32. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158: 360-369.
33. Kapur S, Roy P, Daskalakis J, Remington G, Zipursky RB. Increased dopamine D2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 2001;158:311-314.
34. Kapur S, Zipursky RB, Remington G et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998;155:921-928.
35. Volavka J, Czobor P, Sheitman B et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-262.
36. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM. Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry 1992;160(Suppl. 17):12-16.
37. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:1367-1377.
38. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991;17:263-287.
39. Meltzur HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2, and serotonin2 pKi values. J Pharmacol Exp Ther 1989;251:238-246.
40. Bymaster FP, Rasmussen K, Calligaro DO et al. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry 1997;58(Suppl. 10): 28-36.
41. Henderson DC, Cagliero E, Gray C et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000;157:975-981.
42. Reinstein MJ, Sirotovskaya LA, Jones LE, Mohan S, Chasanov MA. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control. Preliminary findings. Clin Drug Invest 1999;18:99-104.
43. Matthews DE, Farewell VT. The question of sample size. In: Using and Understanding Medical Statistics, 2nd rev. edn. Basel, Switzerland: Karger, 1988: 197-206.
44. Stern RG, Schmeidler J, Davidson M. Limitations of controlled augmentation trials in schizophrenia. Biol Psychiatry 1997;42:138-143.
45. Streiner DL. Thinking small: research designs appropriate for clinical practice. Can J Psychiatry 1998;43:737-741.
46. Guyatt G, Sackett D, Taylor DW, Chong J, Roberts R. Pugsley S. Determining optimal therapy-randomized trials in individual patients. N Engl J Med 1986:314:889-892.
47. Fava GA, Kellner R. Staging: a neglected dimension in psychiatric classification. Acta Psychiatr Scand 1993;87: 225-230.
48. Bleuler M. The long-term outcome of the schizophrenic psychoses. Psychol Med 1974;4:244-254.
49. Meltzer HY. Commentary: defining treatment refractoriness in schizophrenia. Schizophr Bull 1990;16:563-565.
50. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull 1997;23:663-674.
51. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 2001;58:165-171.